NCT03016819

Studies / Phase III

APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma

Advenchen Laboratories · Alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma

recruiting

Sites

0

Patients

4

Target N

325

Enrolled

3

Steps done

0/13

Decisions

6

Design

Title
APROMISS: catequentinib (AL3818) in ASPS, leiomyosarcoma and synovial sarcoma
Design
Randomised by cohort: LMS vs placebo; SS 2:1 vs dacarbazine; ASPS single-arm
Therapy
Catequentinib (AL3818), oral multi-kinase TKI (VEGFR1-3, FGFR1-4, PDGFR, c-Kit, RET)
Primary endpoint
ORR (ASPS); PFS (LMS, SS)

Lifecycle

0 of 13 done

Feasibility assessed

Can this study realistically enroll — sites, patients, timeline?

not started

Protocol drafted & medically reviewed

A protocol synopsis exists, has been linted against SPIRIT, and is through medical review.

not started

Sites activation-ready

Every site's contract, activation and first-patient timeline is within benchmark.

not started

Recruitment funnel and screening plan

Enrollment funnel, accrual pace and eligibility yield computed; candidates to screen proposed per site (import is human-gated).

not started

Sites risk-scored

Per-site KRIs z-scored across the study; statistical outliers get a proposed on-site visit.

not started

Data cleaned

18 edit checks swept AE, DM, SV, EX and LB; deterministic queries auto-closed.

not started

Safety reports triaged

Every reported adverse event triaged with an E2A clock; serious ones with a physician.

not started

Dropout risk scored

Active patients scored; at-risk cohort proposed for outreach.

not started

Termination risk watched

Accrual curve, literature risk profile and registry comparators surveilled; termination itself stays a human decision.

not started

Drug supply forecast

Kits required over the horizon from observed dosing, accrual and discontinuation (partner IRT).

not started

TLFs generated & validated

ICH E3 Section 14 tables from live data (disposition, demographics, exposure, AEs, Kaplan-Meier efficacy), pending double-programming validation.

not started

CSR drafted & signed off

ICH E3 clinical study report assembled from study data; medical sign-off required.

not started

TMF inspection-ready

Trial master file audited against the DIA TMF Reference Model; gaps filed as QA findings.

not started

Sites

0

No sites contracted for this study yet.

Patients

4

Pending decisions

6

assess serious event

Non-serious event needing physician assessment — Grade 1 adverse event, not serious, causality not assessed — investigator assessment required, expectedness undetermined — event not yet coded — under safety physician review (triage only; causality and closure are the physician's)

medium

assess serious event

SAE — SAE Narrative Subject NCT03016819-P02 is a 39-year-old female enrolled in treatment arm Placebo (LMS). The subject experienced an adverse event classified as Grade 3 and reported as serious. The event term has not yet been coded; system organ class is [PENDING — human input]. Source of information: Participant-reported via Luna chat: "I've had a high fever since last night". Solicited symptom report; requires clinical characterization. Onset date: [PENDING — human input] Outcome: [PENDING — human input] Date of resolution (if applicable): [PENDING — human input] Action taken with study treatment: [PENDING — human input] Causality: Investigator causality assessment has not been performed. Causality category is currently unassessed. Investigator causality assessment required before this narrative can be finalized. Expectedness: Expectedness undetermined — event has not yet been coded against the reference safety information. Death within 30 days of event: No. Regulatory reporting: This event has been identified as meeting criteria for expedited reporting under a 15-day timeline (ICH E2A, other serious unexpected event category). The expedited report is due on 2026-10-23. Additional clin [narrative drafted by claude-sonnet-5; verify against source fields]

critical

assess serious event

SAE — SAE Narrative Subject NCT03016819-P02 is a 39-year-old female enrolled in the Placebo (LMS) arm who experienced a serious adverse event, Grade 3 in severity. Event term: [PENDING — human input] (event not yet coded). System organ class: [PENDING — human input]. Onset date: [PENDING — human input]. Source/reported description: Participant-reported via Luna chat: "high fever". Solicited symptom report; requires clinical characterization. Action taken with study treatment: [PENDING — human input]. Outcome: [PENDING — human input]. Date of resolution (if applicable): [PENDING — human input]. Investigator causality assessment: not assessed — investigator assessment required. Causality category on file: unassessed. Expectedness: expectedness undetermined — event not yet coded. Death within 30 days of event: No. Regulatory reporting: This event meets criteria for expedited reporting under ICH E2A as a serious, other unexpected event, subject to a 15-day reporting clock. Expedited report due on 2026-10-23. Narrative summary: A 39-year-old female subject in the Placebo (LMS) arm experienced a [narrative drafted by claude-sonnet-5; verify against source fields]

critical

assess serious event

Non-serious event needing physician assessment — Grade 1 adverse event, not serious, causality not assessed — investigator assessment required, expectedness undetermined — event not yet coded — under safety physician review (triage only; causality and closure are the physician's)

medium

luna withdrawal signal

Participant Grace Nakamura voiced withdrawal intent to Luna. Site coordinator outreach requested — participation is voluntary; only support, never pressure.

medium

luna low mood followup

Participant Grace Nakamura has reported feeling 2/5 then 2/5 in consecutive Luna check-ins. Proactive site outreach proposed.

medium